Virtual Library
Start Your Search
SAID Afqir
Author of
-
+
EP1.09 - Pathology (ID 199)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Pathology
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.09-19 - Molecular Testing in Bronchial Adanocarcinomas: Retrospective Analysis of Pararffine Blocks About 100 Patients in Eastern Morocco (Now Available) (ID 2669)
08:00 - 18:00 | Author(s): SAID Afqir
- Abstract
Background
The search for mutations in lung cancer has become a standard in the current management of this pathology; even more immunotherapy takes up more space in the therapeutic arsenal against this disease; in our department of thoracic surgery we became aware of this evolution; in this work which follows the creation of the electronic registry of lung cancer in our region which was also retained in the work presented at the IASLC summit in Tangier, Africa
Method
This is a retrospective study of 100 patients treated between 2009 and 2017 in our center; only four patients benefited from this research ( only EGFR mutation) in this period ; the authors retrospectively screened all others patients who were diagnosed with stage IIIA through IV adenocarcinoma. We repredited the carefully preserved paraphine blocks. we present through this study the epidemiological profile of EGFR mutations; ALK; KRAS ; as well as looking for PD-1 and PD-L1 checkpoints. The goal is to know the rate of these mutations in a region with a high incidence of 90% metastatic lung cancer.
Result
Molecular testing was possible in 94.9% of the parrafine blocks obtained by excisional biopsy. Our results are being developed; preliminary observations shows the PD-L1 high expression rate was not associated with EGFR, ALK or KRAS molecular alterations. Higher stage (IV) was associated with higher PD-L1. The various proportional cut-offs used to interpret the results can be summarized in this study, which can be reproducibly assessed.
Conclusion
To our knowledge this is the first epidemiological study of genetic mutations of lung cancer; with a significant number of patients in a region of high incidence of this metastatic disease; our results will make it possible to change the management towards targeted therapeutics and immunotherapy
-
+
EP1.17 - Treatment of Early Stage/Localized Disease (ID 207)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Treatment of Early Stage/Localized Disease
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.17-12 - Multimodal Aggressive Managment for Askin' Tumor: Results and Prognosis About 3 Cases (Now Available) (ID 2204)
08:00 - 18:00 | Author(s): SAID Afqir
- Abstract
Background
Peripheral primitive neuroectodermal tumor (pPNET) is a highly aggressive small round cell tumor belonging to PNET/Ewing sarcoma family. Askin's tumor is a rare entity of neuroectodermal pathology that starts from the soft parts of the chest wall. It is observed with predilection in the young subject. Herein ; We discuss follow up of three cases after multimodal therapy.
Method
We report the case of three patients aged respectively 18; 20; 60 years ; whose main symptom in consultation is the appearance of a thoracic parietal mass gradually increasing in size and painful. The general condition was completely preserved in all three patients; and the clinical examination is without abnormalities apart from clubbing in the person aged on a past of smoking. Imaging revealed the presence of a thoracic parietal tumor, the largest of which was 15 X 10X 6 cm without signs of locoregional or distant extension with weak contrast. The histological diagnosis was made on a transparietal mass biopsy with a conclusive immuohistochemical study in favor of a PNET tumor (Askin'tumor)
Result
Management was multimodal with 6 aggressive chemotherapy cycles, followed by extensive carcinologic resection surgery and radiation therapy on the tumor bed. We deplore the loss of a patient after distant recurrence in 8th month ; the other two patients remain alive after 25 and 36 months of progression without recurrence.
Conclusion
Askin's tumor is a bone or extra-bone tumor that is histologically similar to Ewing's sarcoma and PNET, which is characterized by its thoracic location. These three tumors appear to represent different forms of the same entity. They present the same specific chromosomal translocation (11q24-22q12) and, in immunohistochemistry, the same expression of the MIC2 oncogene (CD99) and of the translocation-related FLI-1 protein. The diagnosis is often made at the late stage of locoregional or remote invasion. The treatment is mainly based on surgery and radiotherapy and postoperative chemotherapy to reduce recurrence. The prognosis is unfavorable with a survival at 2 years not exceeding 40% after treatment. Pulmonary metastases are frequently observed even a few years after surgery.
